HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Micelles

Particles consisting of aggregates of molecules held loosely together by secondary bonds. The surface of micelles are usually comprised of amphiphatic compounds that are oriented in a way that minimizes the energy of interaction between the micelle and its environment. Liquids that contain large numbers of suspended micelles are referred to as EMULSIONS.

Networked: 409 relevant articles (43 outcomes, 46 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Torchilin, Vladimir P: 19 articles (01/2010 - 10/2002)
2.	Kataoka, Kazunori: 18 articles (08/2009 - 12/2003)
3.	Nishiyama, Nobuhiro: 15 articles (08/2009 - 12/2003)
4.	Bae, You Han: 14 articles (09/2009 - 07/2003)
5.	Lee, Eun Seong: 13 articles (09/2009 - 07/2003)
6.	Park, Tae Gwan: 11 articles (03/2010 - 12/2003)
7.	Yokoyama, Masayuki: 11 articles (02/2010 - 11/2004)
8.	Kwon, Glen S: 8 articles (03/2010 - 02/2002)
9.	Gao, Jinming: 8 articles (02/2010 - 08/2004)
10.	Allen, Christine: 8 articles (02/2010 - 03/2005)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2009 - "These shell-sheddable biodegradable micelles are highly promising for the efficient intracellular delivery of various lipophilic anticancer drugs to achieve improved cancer therapy." 08/01/2009 - "To the best of our knowledge, our results demonstrated for the first time that polyplex micelles might show improved tumor penetrability over cationic polyplexes, thereby achieving transfection into the inside of the tumor tissue." 01/01/2009 - "This review discusses the most significant and recent developments on specific self-assembled block copolymers as a carrier system such as micelles and vesicles, which can be successfully used to enhance the solubility of hydrophobic drugs, helpful in targeting selective sites in the body, delivering active molecules in a control manner, and reducing the side effects in the treatment of cancer." 09/15/2009 - "The use of block copolymer micelles (BCMs) for the targeted delivery of chemotherapeutics has proven to be a promising approach for improving the therapeutic efficacy of pharmaceutical cancer therapy. " 02/01/2008 - "Tumor growth was significantly delayed and the survival time of mice was prolonged following the treatment by ATRA polymeric micelles demonstrating the improved anticancer activity of ATRA. " Order ALL the reference details at left...
2.	Experimental Arthritis 09/15/2008 - "In vivo pharmacodynamic study based on both carrageenan-induced acute and complete Freund's adjuvant (CFA) induced adjuvant-arthritis models indicated that sustained therapeutic efficacy could be achieved through intraarticular injection of IND-loaded micelles. " 12/01/2006 - "In vivo pharmacodynamic study based on both carrageenan-induced acute and complete Freund's adjuvant-induced adjuvant arthritis model indicated that sustained therapeutic efficacy could be achieved through intraarticular injection of IND-loaded micelles. " Order ALL the reference details at left...
3.	Colorectal Neoplasms (Colorectal Cancer) 08/01/2007 - "In this study, we evaluated the efficacy of SMA-pirarubicin micelles either as single drug or in combination with HBO in a mouse metastatic colorectal cancer model. " 05/01/2008 - "Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil." 07/20/2009 - "Using an in-vitro solid tumor model, multicellular layers(MCL) culture of human colorectal cancer cells, we evaluated the penetration kinetics and efficacy of VEGF siRNA PEC micelles(PEC-siRNA) in comparison to unmodified siRNA(N-siRNA). " 08/01/2007 - "Evaluation of the effect of SMA-pirarubicin micelles on colorectal cancer liver metastases and of hyperbaric oxygen in CBA mice." Order ALL the reference details at left...
4.	Carcinoma (Carcinomatosis) 12/01/2009 - "In vitro antitumor activity tests of DOX-CSO-SA micelles against human breast carcinoma (MCF-7) cells and their multi-drug resistant (MCF-7/Adr) cells presented the reversal activity against DOX resistance MCF-7 cells (MCF-7/Adr). " 07/07/2008 - "Cell viability studies were carried out on human chronic myelogenous leukaemia (K-562) and colon carcinoma cell lines (Caco-2) in order to demonstrate that drug-loaded FA-MPC-DPA micelles exhibited higher cytotoxicities toward cancer cells than unfunctionalized MPC-DPA micelles. " 01/20/2005 - "Due to the ultrasound-enhanced drug intracellular uptake and cell killing, the yield of intraperitoneal (i.p.) ovarian carcinoma tumors decreased from 70% for DOX dissolved in PBS (positive control) to 36% for the same concentration of DOX encapsulated in Pluronic micelles combined with a 30-s sonication of the abdominal region of a mouse (3 mg/kg DOX, i.p. " 08/28/2006 - "In vitro studies using human A2780 ovarian carcinoma cells demonstrated that the cross-linked micelles rapidly internalized and delivered cisplatin into cells. " 11/11/2009 - "The lipid extract of GS-DDG was delivered to human colon carcinoma (Caco-2) cells by solubilizing 0-1000 microg/mL of GS-DDG lipids in 100 microg/mL increments with micelles. " Order ALL the reference details at left...
5.	Breast Neoplasms (Breast Cancer) 08/27/2004 - "Consistent with the in vitro release and CLSM results, a cytotoxicity study demonstrated that DOX-loaded micelles exhibited time-delayed cytotoxicity in human MCF-7 breast cancer cells." 02/01/2008 - "CF-PLU-DOX micelles exhibited greatly enhanced cytotoxicity for MCF-7 human breast cancer cells compared to naked DOX, while CF-PLU copolymer itself showed extremely low cytotoxicity. " 10/08/2007 - "Cytotoxicity assay against a human breast cancer MCF-7 cell line showed that drug nanocarrier based on mixed polymeric micelles can reduce DOX required for cytotoxicity while maintaining the biological activity of the independent polymeric micelles. " 03/01/2007 - "In vivo experiments conducted in a 4T1 mouse breast cancer model demonstrated that DOX-loaded micelles had a longer blood circulation time than free DOX (t(1/2): 30 min and 140 min, respectively). " 10/10/2005 - "The effect of block copolymer structure on the internalization of polymeric micelles by human breast cancer cells." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	1-phenyl-3,3-dimethyltriazene (PDT)
3.	Doxorubicin (Adriamycin)
4.	Folic Acid (Vitamin M)
5.	Carrageenan
6.	Freund's Adjuvant
7.	dioleoyl-N-(monomethoxypolyethylene glycol succinyl)phosphatidylethanolamine
8.	Small Interfering RNA (siRNA)
9.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
10.	Lecithins

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Intra-Articular Injections
3.	Photochemotherapy (Photodynamic Therapy)
4.	Heterologous Transplantation (Xenotransplantation)
5.	Injections

blog comments powered by Disqus

TREATMENT OPTIONS
for Neoplasms,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 20715 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>